News
Barchart on MSN4d
Short Sellers Are Taking Aim at Buy-Rated Tempus AI. Should You Buy TEM Stock Here?Valued at a market cap of $9.2 billion, Tempus AI (TEM) stock went public in June 2024. Since its initial public offering, ...
InvestorsHub on MSN5d
Tempus AI Shares Drop Following Critical Short-Seller Report from Spruce PointTempus AI (NASDAQ:TEM) saw its stock decline by 4% after short-selling firm Spruce Point Capital released a scathing report ...
Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback